Tuesday, April 21, 2026 Issue No. 047 Last Updated 14 Minutes Ago
New York · 58°F · Clear ISSN 2998-4471
Issue No. 047 Tuesday, April 21, 2026 Vol. 3 · Weekly Edition
WellnessWire
1,247 Stories Published Since 2023 Health, With the Receipts.
47,300 Readers · Issue 047
In this week's issue

The Compounding Pharmacy
Reckoning.

Why the quiet wave of 503A enforcement letters matters more than the Ozempic shortage ever did — and the three signals that will decide the next ninety days.

By Priya Natarajan · Reviewed by Dr. Amelia Rhodes · 8 min

Also inside, this week
  • 1 Ozempic shortage: what's actually in the vials
  • 2 Tirzepatide trials, read-in-full
  • 3 NAD+ clinics: follow the money
  • 4 Reviewed — four continuous glucose monitors

The only health newsletter I read top-to-bottom.

— Dr. Amelia Rhodes, Endocrinologist

To subscribe

The Brief is delivered free, Tuesday mornings at 7:00 AM Eastern. Enter an address below. No tracking. One-click unsubscribe.

Free, forever No tracking One-click unsubscribe

47,300 readers
68% open rate
Printed daily at the speed of an email. ISSN 2998-4471. All material © Wellness Wire, 2023–2026.
I.
What you get

Five things in every issue, and nothing else.

  1. № 01

    One story, reported in full

    Every issue leads with a 1,200-word deep read on the week's most consequential story. Not a summary of someone else's reporting.

  2. № 02

    Four links that matter

    Studies, filings, and interviews — annotated. If we link it, we've read it. If we cite a number, we've checked it.

  3. № 03

    A weekly review

    One product, clinic, or protocol, benchmarked against the evidence. Scored out of 10. Conflicts of interest disclosed at the top.

  4. № 04

    Reader mail

    Questions answered by our clinical reviewers — not by an intern with WebMD open. Names used with permission.

  5. № 05

    Zero tracking pixels

    No open tracking. No click tracking. No behavioral ads. Your inbox is yours.

II.
From the mailbag

What readers keep telling us.

The only health newsletter I read top-to-bottom. Their compounding pharmacy reporting was six months ahead of NYT.
Dr. Amelia Rhodes Endocrinologist, Boston
I subscribe to roughly forty newsletters. This is one of three I'd pay real money for — and it's free.
Marcus Chen Health policy analyst
Finally, someone reads the study instead of summarizing the tweet summarizing the press release.
Rachel Okoye Family physician
I forward this to my entire clinic every Tuesday. It's the only reason I know what my patients are reading.
Dr. Theo Laurent Primary care, Minneapolis
III.
Frequently asked

Small print, in large type.

  1. Once a week, Tuesday mornings around 7:00 AM Eastern. Occasionally we send a breaking-news bulletin — maybe three or four times a year — and only if a story genuinely can't wait until Tuesday.

  2. Yes. The Brief is free and always will be. We're supported by a small number of long-read sponsors and by reader-funded memberships for extended reports — both of which are entirely optional.

  3. Every issue has an unsubscribe link at the bottom. One click, no confirmation page, no survey. We keep no record of your address after you leave.

  4. The Brief is written by Priya Natarajan, our founding editor, with contributions from our staff writers and a rotating cast of clinical reviewers. Every piece is fact-checked before it ships.

  5. We send you The Brief. Nothing else. We don't sell, rent, share, or enrich it. We use Buttondown — a small, privacy-first ESP — and we don't use open tracking or click tracking pixels.

  6. Absolutely. Full archives are public at wellnesswire.com/archive, going back to Issue No. 001 in September 2023.

One last thing

Tuesday mornings,
in your inbox.

47,300 clinicians, analysts, and readers-who-read already get it. Take ninety seconds.

Free, forever No tracking One-click unsubscribe